Prosecution Insights
Last updated: October 01, 2026
Application No. 18/611,505

Substituted Bimane Compounds and Methods of Use Thereof

Non-Final OA §103
Filed
Mar 20, 2024
Priority
Mar 20, 2023 — provisional 63/491,184
Examiner
GONZALEZ, LUISALBERTO
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Trustees of the University of Pennsylvania
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
92 granted / 155 resolved
-0.6% vs TC avg
Strong +47% interview lift
Without
With
+47.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
77 currently pending
Career history
219
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
37.4%
-2.6% vs TC avg
§102
12.9%
-27.1% vs TC avg
§112
31.2%
-8.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 155 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Filing Receipt and Priority The filing receipt mailed 06/27/2024 states that the instant application claims benefit of provisional application 63/491,184, filed 03/20/2023. The provisional application supports the instant claims. Therefore, the effective filing date is 03/20/2023. Information Disclosure Statement The information disclosure statement (IDS) submitted 08/01/2024 has been considered. Restriction/Species Election Applicant’s election without traverse of Group I, claims 1-10, is acknowledged. PNG media_image1.png 120 196 media_image1.png Greyscale At examiner’s discretion, search and examination has been broadened to include the full scope of compound of general formula (I), shown below. PNG media_image2.png 94 144 media_image2.png Greyscale Claims 11-20 are hereby withdrawn being drawn to a non-elected invention. Claim Objections Claim 4 contains the typo “Rc6” where it should state “R6c”. Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. KSR Rationale The MPEP in section 2143, subsection I gives examples of Rationales for supporting a conclusion of obvious. These rationales are non-exhaustive and include (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Claim(s) 1-4 is/are rejected under 35 U.S.C. 103 as being unpatentable over Szumski (Synlett, 2021, 32, 1141-1145). Claim 1 claims a compound of formula (I), shown above. Claims 2-3 are drawn to embodiments wherein at least one to all of R1-R3 are either C1-C6 alkyl (claim 2) or CH3 (claim 3). Claim 4 claims embodiments wherein L is one of the following PNG media_image3.png 80 174 media_image3.png Greyscale or R5 is one of the following PNG media_image4.png 100 242 media_image4.png Greyscale . Regarding claims 1-4, Szumski on p. 1142, Fig. 2 teaches the following compound 3a. PNG media_image5.png 164 384 media_image5.png Greyscale Compound 3a differs from the instant claims in that the alkynylenyl-aryl of R4 (instant claim 1) is located at the R3 position instead. R1 and R2 are methyl and halogen, respectively, which embrace the limitations of claims 2-3. The substituted aryl group embraces the limitations of claim 4. The compounds are positional isomers and one of ordinary skill would expect similar properties between the two. The MPEP states: “"An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979).” One of ordinary skill in the art would be able to reach the instant claims by modifying the compound of Szumski to have the alkynylenyl-aryl moiety at position R4 instead of R3. Therefore, it would have been prima facie obvious to one of ordinary skill in the art to have modified the compound of Szumski to arrive at the instant claims. One of ordinary skill would be motivated to make the modification as one of ordinary skill would expect the compounds to have similar properties. Allowable Subject Matter Claims 5-10 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1-4 are rejected. Claims 5-10 are objected against. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUISALBERTO GONZALEZ whose telephone number is (571)272-1154. The examiner can normally be reached M-F 8:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LUISALBERTO GONZALEZ/Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Mar 20, 2024
Application Filed
Aug 28, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12708620
PRODRUGS AND MEDICAL USES THEREOF
5y 8m to grant Granted Aug 18, 2026
Patent 12708622
METHODS OF TREATING CANCER AND INHIBITING TYK2 AND MEK
3y 9m to grant Granted Aug 18, 2026
Patent 12698271
CRYSTALLINE FORM OF A SHP2 INHIBITOR
2y 10m to grant Granted Aug 04, 2026
Patent 12662481
SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
4y 5m to grant Granted Jun 23, 2026
Patent 12655161
Solid Forms of an eIF4E Inhibitor
2y 12m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+47.2%)
2y 10m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 155 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month